Governor Ron De Santis touted it as an " early treatment for keeping people out of the hospital and reducing mortality.". Monoclonal antibodies are administered either subcutaneously or as an intravenous infusion. The expert clinicians agree that my best hope is Humira (generic name, adalimumab), one in a class of drugs known as monoclonal antibodies that block the immune system proteins that make joints . See Limitations of Authorized Use. Continue to use the same codes to bill for administering bamlanivimab and etesevimab for PEP and treatment: Effective February 11, 2022, CMS updated the Medicare payment rates for the administration of COVID-19 monoclonal antibody products by intravenous (IV) injection. Healthcare providers must be able to recognize patients at risk for progression to severe disease who would benefit from monoclonal antibody infusion and recognize which patients must be hospitalized for severe infection. As a result, CMS issued a new product code for REGEN-COV of 600 mg (Q0240) and 2 new codes for the administration of repeat doses of REGEN-COV (M0240/M0241). Convalescent plasma has side effects like monoclonal antibodies, but with more infusion reactions and less efficacy. For most Medicare Advantage hospice patients, submit claims to Original Medicare. The federal government isn't distributing the following products; you may purchase them through typical purchasing channels: Medicare will cover and pay for the administration of monoclonal antibodyinfusions and injectionsused for post-exposure prophylaxis or treatment of COVID-19(when furnished consistent with their respective approvals or EUAs) the same way it covers and pays for COVID-19 vaccines until the end of the calendar year in which the EUA declaration for COVID-19 drugs and biologicals ends. For example, if you administer 200mg of tocilizumab in 1 infusion, you should add 200 as the number of units on the claim. Children younger than 12 years of ageUse and dose must be determined by your doctor. 1.6%).[28]. Check the Batch # on the vial. In the clinical trial, molnupiravir was given to study participants in four capsules twice a day for five daysstarting within five days after patients experienced the first symptoms of COVID-19.. There are now Regeneron monoclonal antibody treatment clinics in Jacksonville, Ormond . Possible side effects of COVID-19 monoclonal antibodies can include: nausea or vomiting diarrhea fever or chills drop in blood pressure headache or dizziness muscle pains or aches itching. Monoclonal antibody therapy is indicated for use in non-hospitalized patients with mild to moderate disease who have risk factors for progression to severe disease. Effective for services furnished on or after December 8, 2021, the Medicare payment rate for administering COVID-19 monoclonal antibody products through intramuscular injection for pre-exposure prophylaxis (such as tixagevimab co-packaged with cilgavimab, administered as 2 separate consecutive intramuscular injections), in select patient populations, is approximately $150.50. If the Batch # is D534422, the product was commercially-purchased. Although the Food and Drug Administration gave these treatments like Regeneron emergency use authorization in 2020, the criteria for who is eligible to receive them has expanded. A one-time dose of two long-acting monoclonal antibodies reduced the risk of developing symptomatic COVID by 77% in comparison with placebo ( P < .001) in a randomized, double-blind, placebo . Medicare Part B will provide payment for the drug and its administration under the applicable Medicare Part B payment policy when you provide it in the outpatient setting, according to the FDA approval. Typical side effects include pain at the injection site, fever, fatigue, headache, muscle pain, chills and diarrhoea. [6] On April 5, 2022, the FDA announced that, due to the high frequency of the Omicron BA.2 sub-variant, sotrovimab isnt currently authorized in any U.S. region. As with payments for administering other COVID-19 monoclonal antibodies, the separate Medicare payment amount of $450 per infusion of ACTEMRA applies to all hospitals not paid reasonable cost for furnishing these products consistent with the FDA approval or EUA. http://creativecommons.org/licenses/by-nc-nd/4.0/ Serious side effects were rare in Evusheld's PROVENT trial, although some participants experienced serious cardiac adverse events, including myocardial infarction and heart failure. Monoclonal antibodies boost the immune system after you are already sick, speeding up your immune response to prevent COVID-19 from getting worse. Monoclonal antibodies, like most medications, carry risks and side effects that you and your doctor need to weigh against any possible benefits. Monoclonal antibodies may block the SARS-CoV-2 virus from attaching to human cells and help neutralize the virus (meaning they stop the virus from replicating). If your hospice patients Medicare Advantage plan participates in the Hospice Benefit Component of the Value-Based Insurance Design (VBID) Model, submit claims for administering COVID-19 monoclonal antibody products to the Medicare Advantage Plan. The most commonly reported side effect was diarrhea (1%).[22]. You can decide how often to receive updates. Early evidence suggests that mAbs administered by an infusion or an injection can reduce the amount of COVID-19 virus present in someone infected with COVID-19. Doessegger L, Banholzer ML. As with naturally occurring antibodies, monoclonal antibodies stimulate the immune system to act against disease-causing agents. pain. A federal government website managed and paid for by the U.S. Centers for Medicare & Medicaid Services. Secure .gov websites use HTTPSA [7][8]Monoclonal antibodies have been in use since 1985 and have been used as therapies for malignancy, autoimmune disease, infectious organisms, and drug reversal. Get the most current list of billing codes, payment allowances, and effective dates for currently authorized monoclonal antibody products. Doctors have alternate therapies to battle early. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. Note: On April 16, 2021, the FDA revoked the EUA for bamlanivimab when administered alone. The FDA provides the information regarding proper dosing, storage, handling, and administration on the fact sheets issued for healthcare providers on the emergency use authorization for the three monoclonal antibodies that are currently available. TGC has proven to be of value in treatment of multidrug-resistant infections, but therapy can be complicated by multiple dangerous side effects, including direct drug toxicity. Providers and suppliers may bill for the higher home payment rate when they furnish a COVID-19 monoclonal antibody product in a home or residence. This includes circumstancessuch as a Medicare patients permanent residence, temporary lodging (for example, hotel or motel, hostel, or homeless shelter), and homes or residences that have been made provider-based to the hospital during the COVID-19 PHE. Monoclonal antibodies targeting the spike protein of the SARS-CoV-2 have yielded positive in vitro results. Heres how you know. If your Medicare patients permanent residence is a setting that provides health care services, such as an intermediate care facility, nursing facility, or skilled nursing facility, that setting would also qualify as a home or residence for purposes of billingcodes M0241, M0244, M0246, M0248, or M0223. Monoclonal antibodies are intended for the treatment of outpatient mild-moderate COVID-19 infections in patients with risk factors for progression to severe disease. website belongs to an official government organization in the United States. Prajapat M, Handa V, Sarma P, Prakash A, Kaur H, Sharma S, Bhattacharyya A, Kumar S, Sharma AR, Avti P, Medhi B. Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. An EUA for sotrovimab for treatment of COVID-19. Effective February 11, 2022, Medicare established separate coding and payment for administering COVID-19 monoclonal antibody products through IV injection in a patients home or residence. Monoclonal antibody treatments are infusions of lab-made proteins that mimic the immune system's ability to fight off COVID. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. ( Patients of older age with comorbidities such as cardiovascular disease, obesity, diabetes, chronic kidney disease, and chronic lung disease are at much higher risk of developing severe symptoms and requiring hospitalizations than younger healthy individuals. Smith Park in Pembroke Pines. However, these side-effects waned within 48 h. Pain at the injection site was the most common local side-effect, while fatigue, fever, headache and muscle pain were frequently repo Medicare also pays for treatment to address major complications: For COVID-19 monoclonal antibody products administered before May 6, 2021, the Medicare payment rate is approximately $310. The goal of this therapy is to help prevent hospitalizations, reduce viral loads, and lessen symptom severity. For many providers and suppliers, CMS also geographically adjusts this ratebased on where youfurnishthe service. Flu-like symptoms (fever, sweating, chills, cough, sore throat, headache or muscle pain) Upset stomach (nausea, vomiting or diarrhea) Itching, swelling, rash or hives. Theres no cost sharing for people with Medicare for COVID-19 monoclonal antibody products or their administration. ( Antibodies are parts of your immune system. [23][24]Infusion-related reactions are characterized by flushing, fever/chills, back or abdominal pain, nausea/vomiting, pruritus, or skin rashes. Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. As demonstrated above, monoclonal antibody therapy used in the treatment of outpatient COVID-19 in patients at risk for developing severe disease has the potential to decrease hospitalizations and mortality. Medicare will only cover and pay for bamlanivimab (administered alone) if it was furnished, consistent with the terms of the EUA, between November 10, 2020 - April 16, 2021. Tixagevimab and cilgavimab are long-acting monoclonal antibodies meant to directly target the spike protein of SARS-CoV-2 and block the virus' attachment to and invasion of your cells. Scientists have wondered if infection with SARS-CoV-2 could also result in the production of autoantibodies in people who didn't have them before they got sick. They are exact copies of one . Effective for IV injection services furnished on or after February 11, 2022 (such as the administration of bebtelovimab), the Medicare payment rate for administering these COVID-19 monoclonal antibody products, authorized or approved by the FDA, is approximately $350.50. There are several variants of concern that have been identified, such as the Alpha variant (B1.1.7 lineage, UK origin), Beta variant (B.1351 lineage, South African origin), Gamma variant (P.1/B.1.1.28.1 lineage, Brazilian origin), Delta variant (B1.617.2 lineage, Indian origin). Monoclonal antibody therapy is not indicated in severe cases requiring hospitalization. ) After receiving monoclonal antibody therapy, the patient must continue self-isolating and use infection control measures such as social distancing, frequent handwashing, mask-wearing, cleaning, and disinfecting high-touch surfaces to the CDC. Monoclonal antibodies are one such treatment that may . Researchers founda reduction in combined hospitalizations and death with 1% in the treatment group and 7% in the placebo group. [5][6], Monoclonal antibodies have been identified as a potential therapy to prevent disease progression in patients at risk for severe disease. Monoclonal antibody therapy is a way of treating COVID-19 for people who have tested positive, have had mild symptoms for seven days or less, and are at high risk for developing more serious symptoms. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. They are considered a promising approach in managing nonhospitalized patients with mild to moderate COVID-19 who are at high risk of developing severe illness. Starting August 15, 2022, bebtelovimab will be commercially available. Medicare will pay approximately $450 per infusion when 2 infusions are clinically necessary. The antibodies . In these situations, use the following HCPCS codes to bill for casirivimab and imdevimab: The September 16, 2021, revised EUA for bamlanivimab and etesevimab allows for its use for PEP in certain adult and pediatric patients. The most common side effects include allergic reactions, which include infusion related reactions, injection site reactions, brief pain, weakness and others. Lpez-Medina E, Lpez P, Hurtado IC, Dvalos DM, Ramirez O, Martnez E, Dazgranados JA, Oate JM, Chavarriaga H, Herrera S, Parra B, Libreros G, Jaramillo R, Avendao AC, Toro DF, Torres M, Lesmes MC, Rios CA, Caicedo I. We geographically adjust the rate based on where you furnish the service. Risk factors for severe and critically ill COVID-19 patients: A review. This rate reflects information about the costs involved in furnishing these products in a patients home. Antibodies to SARS-CoV-2, the virus that causes COVID-19, can be detected in the blood of people who have recovered from COVID-19 or people who have been vaccinated against COVID-19. However, this COVID-19 therapy may cause several side effects such as mild pain, bleeding, bruising of the skin, soreness, swelling, thrombotic-type episodes, arterial hypertension, changes in heart activity, slowed bone marrow activity, impaired renal function, diarrhea, fatigue, nausea, vomiting, allergic reaction, fever, and possible 1 Side effects: Nausea is the most common side effect. Remdesivir is an antiviral drug approved by the FDA for the treatment of COVID-19 in hospitalized adults and hospitalized pediatric patients at least 12 years of age. In this article we take a closer . Not many people have received bebtelovimab. Vaccines prevent progression for a larger part of the population. If you administer these COVID-19 monoclonal antibody products in Medicare patients in traditional health care locations (for example, a hospital outpatient infusion clinic or freestanding infusion clinic), continue to bill HCPCS code M0220, as applicable. The pharmacy staff should be aware of the proper storage and handling of the medications. There may not be data from patients, but lab studies strongly suggest the treatments will not help omicron-infected people. [9][10][11]The only monoclonal antibody currently authorized for emergency use in the United States by the FDA is sotrovimab. While individuals of all ages are at risk of contracting COVID-19 and developing severe disease, several risk factors have been identified that place patients at higher risk for morbidity and mortality. Effective for services furnished on or after May 6, 2021, the Medicare payment rate for administering COVID-19 monoclonal antibody products through infusion in a patients home or residence is approximately $750. Most people experience no side effects from monoclonal antibodies for COVID-19. Serious and unexpected side effects may happen. Adults and children 12 years of age and olderAt first, 600 milligrams (mg) (two 300 mg injections) injected under the skin at different injection sites. Bamlanivimab (EUA issued November 9, 2020, EUA revoked April 16, 2021). Talk to your healthcare provider if you experience any of the following in the days after monoclonal antibody treatment: Chills Diarrhea Fatigue Fever Muscle aches and pains Nausea Vomiting Cytokine Release Syndrome Because CMS considers monoclonal antibody products to treat COVID-19 to be COVID-19 vaccines, they arent eligible for the New COVID-19 Treatments Add-on Payment (NCTAP) under the Inpatient Prospective Payment System (IPPS). They are accessible on an outpatient basis, via a single infusion or four injections. Dont bill for USG-purchased products. [5]Given the limited clinical situations allowed under the FDA approval and EUA, you should only bill for ACTEMRA (tocilizumab) on a 12x type of bill (TOB). COVID-19 vaccines protect against the SARS-CoV-2 virus only, so it's still important to keep yourself healthy and well. Get the most current payment allowances and effective dates for these products. Health authorities worldwide continue to encourage those who receive a COVID-19 vaccine to report any side effects to a healthcare professional. An EUA for bamlanivimab and etesevimab for COVID-19. Monoclonal antibody therapy is not indicated for patients requiring supplemental oxygen or patients that already require supplemental oxygen thatare now requiring increased support.[13][12][14]. StatPearls Publishing, Treasure Island (FL). Xia ZN, Cai XT, Cao P. Monoclonal antibody: the corner stone of modern biotherapeutics. Monoclonal antibodies are lab-made proteins that mimic the immune system's ability to fight off viruses and other harmful pathogens, per the FDA. The emergency use authorization(EUA) for sotrovimab is for use in non-hospitalized patients 12 years or older, weighing more than 40 kg, with mildor moderate symptoms, who have one or more risk factors for progression to severe disease. A monoclonal antibody (mAb) is a type of immune protein produced in a lab that binds to a specific protein on a cell called an antigen . Monoclonal antibodies are laboratory-made "substitute antibodies" that can help the immune system recognize and respond more effectively to COVID-19, according to the U.S. Food and Drug. The FDA approved or authorized under EUA the followingadditional investigational monoclonal antibody therapies: The FDA authorized the use of these monoclonal antibody therapies to treat mild-to-moderate COVID-19 in adults and pediatric patients when both of these apply: Health care providers may administer these monoclonal antibody therapies only in settings where they have both of these: Under the terms of the FDA approval and EUA, health care providers may only administer ACTEMRA (tocilizumab) to hospitalized patients with severe COVID-19 illness. Then, your dose will be reduced to 300 mg every other week. The authorized dose for REGEN-COV for. How you take it: Via injection or IV and administered only in a health care setting by a health care professional. means youve safely connected to the .gov website. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. or The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent in COVID-19, has created a global pandemic and overwhelmed hospital systems globally. While the initial data regarding monoclonal antibodies in the treatment of COVID-19 appears promising, at this time, thebulk ofthis data is preliminary and unpublished and has not been peer-reviewed. Most infusion-related reactions are self-limited and treated by stopping the infusion and symptomatic treatment. COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. Monoclonal antibodies used for the treatment of COVID-19 target the viral spike protein, which prevents viral entry. This activity outlines the indications, actions, contraindications, and adverse events for monoclonal antibody therapy as a valuable treatment for outpatient COVID-19 infections. Learn more about what to do if you are sick. On January 24, 2022, the FDA announced that, Sotrovimab (EUA issued May 26, 2021, latest update February 23, 2022). Treatment Locator Side effects can range from mild to serious and may include: Wheezing or trouble breathing. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Bebtelovimab (EUA issued February 11, 2022, latest update October 27, 2022). [21], The major benefits derived from the monoclonal antibody therapies appear to be a reduction in viral load, hospitalizations, and death. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on healthcare facilities, and even save lives. In vitro studies have shown that sotrovimab maintains spike neutralizing activity against all variants of concern, including Omicron. Blood tests show even after three doses of Pfizer's vaccine, she has no detectable antibodies against Covid-19. [2][3][4]At this time, however, there is minimal data that suggests these therapies improve outcomes. This likely will bring more attention to this treatment, which has proven to cut . For example, Medicare will pay 95% of AWP for COVID-19 vaccines provided in the physician office setting, and pay hospital outpatient departments at reasonable cost for COVID-19 vaccines. Benefits And Risks Of Administering Monoclonal Antibody Therapy For Coronavirus (COVID-19). Describe the mechanism of action of monoclonal antibodies used for the treatment of COVID-19. For many providers and suppliers, we also geographically adjust this rate based on where you furnish the service. Millions of vaccinated people have experienced side . As with payments for administering other COVID-19 monoclonal antibodies, the separate Medicare payment amount of $450 per infusion of ACTEMRA applies to all hospitals not paid reasonable cost for furnishing these products consistent with the FDA approval or EUA. Get the. They seek out the antigens (foreign materials) and stick to them in order to destroy them. Common side effects of monoclonal antibodies include: Allergic reactions Chills Weakness Diarrhea Nausea Vomiting Rash Itching High blood glucose levels Cough Constipation Other side effects of monoclonal antibodies include: Shortness of breath Peripheral edema Headache Fever Muscle aches and pain Decreased appetite Increased triglyceride levels Providers and suppliers who administer REGEN-COV for PEP should use M0243 or M0244 for administering the first dose and M0240 or M0241 for administering subsequent repeat doses. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. Monoclonal antibodies are intended to trigger the immune system and, in doing so, the body may respond with flu-like symptoms. See the Federal Register announcement for more information about the revoked EUA and NDA approval. This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) The cause wasdemonstrated to be anovel coronavirus, called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Previously authorized monoclonal antibodies had their authorizations revoked in January 2022 with the emergence of the Omicron variant. Effective for services furnished on or after February 11, 2022, the Medicare payment rate for administering COVID-19 monoclonal antibody products through IV injection (such as bebtelovimab) in a patients home or residence is approximately $550.50. Healthcare providers must also educate the patient on symptoms that mark progression to severe disease and prompt the patient to return for reevaluation. Pregnant people. Therefore, youmay not administerREGEN-COVfor treatment or post-exposure prevention of COVID-19 under the EUA until further notice. CMS pays for tocilizumab based on the number of units administered, so you should include the total number of units administered on the claim per day. Under the terms of the EUA, tocilizumab may only be infused in the hospital setting, in limited clinical situations. The new rate reflects updated information about the costs involved in administering monoclonal antibody products for different types of providers and suppliersand the resources necessary to ensure providers administer the products safely and appropriately. J0248 represents 1mg, and you should report units to reflect the dosage you administered for each patient. Managing Chemotherapy Side Effects: Achieving Reliable and Equitable Outcomes. Few cases of anaphylaxis have been reported. Administration ofSotrovimab should occur within 10 days of symptom onset. Watch for Eli Lilly to release more information about future batch numbers. The July 30, 2021, revised EUA for casirivimab and imdevimab allows for its use for post-exposure prophylaxis (PEP) for certain patients who have been exposed to (or are at high risk of exposure to) a person with COVID-19. Bayer V. An Overview of Monoclonal Antibodies. Wegeographically adjustthe rate based on where you furnish the service. Providers may not furnish tocilizumab in the home or residence, including homes or residences that have been made provider-based to the hospital during the COVID-19 PHE. Medicare will establish codes and rates for administering new products as the FDA approves or authorizes each product. The interprofessional healthcare team is also responsible for educating the patient on infection control measures. The Medicare payment rate of approximately $450 for the administration of COVID-19 monoclonal antibody products will apply for the administration of ACTEMRA when you furnish it in accordance with the FDA approval or EUA. For dates of service on or after August 15, only bill Medicare if you use commercially-purchased products. Choi JC, Kim WY. Evusheld is the only non-vaccine with emergency use authorization (EUA) from the FDA to prevent infection from COVID-19 before you're exposed to the virus. [2]On July 30, 2021, the FDA revised the EUA for REGEN-COV (casirivimab and imdevimab, administered together) to allow its use for post-exposure prophylaxis (PEP) in certain adult and pediatric patients. Identify the potential adverse reactions to monoclonal antibody therapy in the management of outpatient COVID-19. Medicare will pay approximately $450 per infusion when 2 infusions are clinically necessary. Inpatient locations, such as inpatient hospitals, inpatient psychiatric hospitals, long-term care hospitals, and inpatient rehabilitation hospitals, would never qualify as the home or residence for purposes of HCPCS code M0221. Official websites use .govA This rate reflects updated information about the costs involved in furnishing these complex products in a patients home. [16]This receptor is found on the respiratory epithelium, upper esophagus, ileum, myocardium, proximal tubular cells in the kidney, and the urothelium of the bladder. As mentioned above,the FDA revoked its authorizations for previously authorized monoclonal antibodies as they did not maintain efficacy against the Omicron variant. You are not required to obtain permission to distribute this article, provided that you credit the author and journal. Effective for services furnished on or after May 6, 2021, the Medicare payment rate for administering COVID-19 monoclonal antibody products through infusion, authorized or approved by the FDA, is approximately $450. With the dominance of this variant in the United States and the lack of readily available testing to identify the infecting variant, the FDA recommended against the use of any monoclonal antibody at this time except sotrovimab. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Brggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA. Clinical development methodology for infusion-related reactions with monoclonal antibodies. CMS geographically adjusts the rate based on where you furnish the service. Hypersensitivity, including infusion-related and . As the COVID-19 pandemic has overwhelmed hospital systems worldwide, the need arose for outpatient therapies and strategies to decrease hospitalizations and identify patients at risk for developing severe diseases. CMS will continue to pay for COVID-19 monoclonal antibodies for post-exposure prophylaxis or for treatment of COVID-19 under the Medicare Part B vaccine benefit through the end of the calendar year in which the EUAdeclaration for COVID-19 drugs and biologicalsends. The word "monoclonal" refers to the fact that the antibodies created in the laboratory are clones. Shepard HM, Phillips GL, D Thanos C, Feldmann M. Developments in therapy with monoclonal antibodies and related proteins. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. These antibodies are typically. COVID-19 VEKLURY(Remdesivir) in the Outpatient Setting. Get themost current geographically adjusted rates. Mitj O, Corbacho-Monn M, Ubals M, Alemany A, Suer C, Teb C, Tobias A, Peafiel J, Ballana E, Prez CA, Admella P, Riera-Mart N, Laporte P, Mitj J, Clua M, Bertran L, Sarquella M, Gaviln S, Ara J, Argimon JM, Cuatrecasas G, Caadas P, Elizalde-Torrent A, Fabregat R, Farr M, Forcada A, Flores-Mateo G, Lpez C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiones C, Ramrez-Viaplana F, Reyes-Uruea J, Riveira-Muoz E, Ruiz L, Sanz S, Sents A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, Gonzlez-Beiras C, Clotet B., BCN-PEP-CoV2 Research Group.